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Background: While prior research has provided important information about readmission rates following
percutaneous coronary intervention, reports regarding charges and length of stay for readmission beyond 30 days
post-discharge for patients in a large cohort are limited. The objective of this study was to characterize the
rehospitalization of patients with acute coronary syndrome receiving percutaneous coronary intervention in a U.S.
health benefit plan.
Methods: This study retrospectively analyzed administrative claims data from a large US managed care plan at
index hospitalization, 30-days, and 31-days to 15-months rehospitalization. A valid Diagnosis Related Group code
(version 24) associated with a PCI claim (codes 00.66, 36.0X, 929.73, 929.75, 929.78–929.82, 929.84, 929.95/6, and
G0290/1) was required to be included in the study. Patients were also required to have an ACS diagnosis on the
day of admission or within 30 days prior to the index PCI. ACS diagnoses were classified by the International
Statistical Classification of Disease 9 (ICD-9-CM) codes 410.xx or 411.11. Patients with a history of transient ischemic
attack or stroke were excluded from the study because of the focus only on ACS-PCI patients. A clopidogrel
prescription claim was required within 60 days after hospitalization.
Results: Of the 6,687 ACS-PCI patients included in the study, 5,174 (77.4%) were male, 5,587 (83.6%) were
<65 years old, 4,821 (72.1%) had hypertension, 5,176 (77.4%) had hyperlipidemia, and 1,777 (26.6%) had diabetes.
At index hospitalization drug-eluting stents were the most frequently used: 5,534 (82.8%). Of the 4,384 patients who
completed the 15-month follow-up, a total of 1,367 (31.2%) patients were rehospitalized for cardiovascular
(CV)-related events, of which 811 (59.3%) were revascularization procedures: 13 (1.0%) for coronary artery bypass
graft and 798 (58.4%) for PCI. In general, rehospitalizations associated with revascularization procedures cost more
than other CV-related rehospitalizations. Patients rehospitalized for revascularization procedures had the shortest
median time from post-index PCI to rehospitalization when compared to the patients who were rehospitalized for
other CV-related events.
Conclusions: For ACS patients who underwent PCI, revascularization procedures represented a large portion of
rehospitalizations. Revascularization procedures appear to be the most frequent, most costly, and earliest cause for
rehospitalization after ACS-PCI.* Correspondence: bae_Jay@lilly.com
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Acute coronary syndrome (ACS) includes ST-segment
elevation myocardial infarction (STEMI), non-ST-segment
elevation myocardial infarction (NSTEMI), and unstable
angina (UA). Approximately 733,000 patients discharged
from the hospital in 2006 had a primary diagnosis of ACS
[1]. ACS can lead to both mortality and morbidity during
and after hospitalization, with up to 30% of discharged
patients needing rehospitalization within 6 months [2-4].
ACS management includes treating evolving acute
STEMI, and preventing the progression of UA and
NSTEMI into acute STEMI and death, by hospitalization
and the use of antiplatelet and anticoagulant therapy,
either alone or combined with early revascularization
[2,5]. Percutaneous coronary intervention (PCI) is gen-
erally recommended for patients with either STEMI or
NSTEMI/UA. PCI represents medical procedures (such
as bare-metal stents [BMS] or drug-eluting stents [DES]
and balloon angioplasty) that use “mechanical” means to
treat patients with partially or completely restricted
blood flow through an artery of the heart [6]. Only 25%
of hospitals in the United States have the equipment,
expertise, and facilities to administer PCI, and these
hospitals are referred to as PCI-capable hospitals [6].
An estimated 1,313,000 PCI procedures were per-
formed in the United States in 2006; approximately
65% on men and approximately 50% were performed
on patients ≥65 years old [1]. In 2006, approximately
76% of stents used during PCI were DES with the
remaining 24% being BMS [1].
Hospital readmission rates following PCI are an import-
ant measure of quality of care and also have important
economic implications for the overall healthcare system.
In general, the National Quality Forum has adopted the
rate of rehospitalization as an important measure of
hospital quality and the Centers for Medicare and
Medicaid Services (CMS) has recommended that
rehospitalization rates be incorporated as a measure
for value-based hospital reimbursement [7,8].
While prior research has provided important informa-
tion about readmission rates following PCI, reports
regarding charges and length of stay (LOS) for readmis-
sion beyond 30 days post-discharge for ACS-PCI patients
in a large cohort are limited. Previous research investigat-
ing rehospitalization has focused on specific subpopu-
lations (such as Medicare fee-for-service), 30-day and
1-year rehospitalization, predictors of rehospitalization,
and total costs over a 1-year period [9-11]. The primary
objective research questions of the current study were
from the managed care perspective and included the fol-
lowing: What is the rate of rehospitalization for
commercially-insured ACS-PCI patients at 30 days post-
index PCI? What is the rehospitalization rate within
15 months? What procedures and diagnoses wereassociated with these rehospitalizations? What was the
LOS and charges associated with these rehospitalizations?
Methods
This retrospective database analysis used administrative
claims data to characterize ACS-PCI patients in a large
US managed care plan at index hospitalization, 30-days,
and 31-days to 15-months rehospitalization. Data were
analyzed in a manner compliant with the Health Insur-
ance Portability and Accountability Act, and no identifi-
able protected health information was extracted. This
research study involved analysis of pre-existing, de-
identified data and was therefore not reviewed by an In-
ternal Review Board.
The study cohort included commercially insured
patients, with both medical and pharmacy benefits, who
received a PCI between January 1, 2006 and December
31, 2006. Figure 1 presents the study’s sample selection
process. A valid Diagnosis Related Group (DRG) code
(version 24) associated with a PCI claim was required
for patients to be included in the study. In addition, con-
tinuous enrollment in a health plan was required for at
least 12 months prior to the PCI, which was defined as
the baseline period. No minimum continuous enroll-
ment was required post-PCI. For patients with more
than one PCI procedure, the first PCI in 2006 was con-
sidered the index event. If more than one DRG code was
identified for a single hospitalization, the highest
weighted DRG code (according to CMS criteria) was
assigned. Patients selected for this study were required
to have an ACS diagnosis on the day of admission or
within 30 days prior to the hospitalization for the index
PCI procedure. The ACS diagnoses were classified by Inter-
national Statistical Classification of Disease 9 (ICD-9) codes
as either STEMI (410.xx other than 410.7), NSTEMI
(410.7), or UA (411.1). The diagnosis and procedure codes
used to identify patients are summarized in Additional file 1:
Diagnosis and Procedure Codes. In order for our ana-
lyses to be applicable to both clopidogrel and prasu-
grel (though not commercially available in the time
frame of our study), patients who had a diagnosis of
transient ischemic attack or stroke at any time prior
to the index PCI, within or before the 12-month
baseline period, were excluded. Because clopidogrel
has been the standard medical treatment for ACS-PCI,
patients were also excluded if they did not have at least
one prescription for clopidogrel within 60 days of the
initial PCI hospital admission. Patients not receiving
anti-platelet therapy after PCI have previously been
shown to have different characteristics, behaviors, treat-
ment, and outcomes [12] and were therefore outside the
scope of the current study. Clopidogrel is preferred over
ticlopidine and is more widely used, with ticlopidine
comprising less than 0.1% of the utilization [13,14]. The
2006 commercially insured 
population 
N = 13,431,566
Patients excluded b/c no PCI 
hospitalization and/or continuous 
12 months of enrollment
N = 13,419,421
Patients who received a PCI b/w
1/1/2006 and 12/31/2006 with
continuous enrollment at least 12 
months prior to PCI 
N = 12,145
Patients excluded b/c no ACS 
diagnosis on day of index PCI 
hospitalization admission or 
within 30 days prior to index PCI
(e.g. elective PCI)
N = 3,657
Patients with ACS diagnosis on 
the day of index PCI 
hospitalization admission or 
within 30 days prior to index PCI 
N = 8,488
Patients excluded b/c of diagnosis 
of TIA or stroke prior to the index 
PCI, within or before the 
12-month baseline
N = 997
Patients with no history of TIA or 
stroke at any time prior to the 
index PCI, within or before the 
12-month baseline
N = 7,491
Patients excluded b/c did not fill 
at least one clopidogrel 
prescription within 60 days of the 
index PCI 
N = 804
Patients who filled at least one 
clopidogrel prescription within 60 
days of the index PCI 
N = 6,687
Figure 1 Flow diagram of sample selection. Abbreviations: ACS = acute coronary syndrome; b/c = because; b/w=between; PCI = percutaneous
coronary intervention; TIA = transient ischemic attack.
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patients who could have left the hospital with a sup-
ply of clopidogrel and/or were prevalent users of
clopidogrel prior to index hospitalization. Use of
over-the-counter medication such as aspirin was not
observable in this data source.
Patient characteristics of interest included demo-
graphic and healthcare-related variables. Treatment pat-
terns at index hospitalization were grouped into 4
categories based on DRG codes: PCI, coronary artery by-
pass graft (CABG), cardiac-related (other than PCI or
CABG), and non-cardiac-related. The type of stent used
(at least one DES, BMS only, or no stent) was deter-
mined from the DRG code description for the index
PCI. Comorbidities such as diabetes (250.xx), hyperlipid-
emia (272.xx), and hypertension (401.xx through 405.xx)
were determined using ICD-9 codes in the claims
records for the 12-month pre-PCI baseline period. The
follow-up period was 15 months beginning on the dis-
charge date of the index hospitalization. The number of
days, if any, before rehospitalization was defined as the
number of days between initial discharge and readmis-
sion date.Of the 6,687 patients in the initial hospitalization cohort,
frequency distributions for first rehospitalization were
dichotomized into “all-cause” and cardiovascular-related,
“CV-related”. The categories were based on the DRGs
assigned at rehospitalization and for CV-related the cat-
egories included stroke (DRG 014); revascularization pro-
cedures (106, 518, 555, 556, 557, 558); heart failure and
shock (127); chest pain (143); and other CV (124, 125,132,
144, 515), which includes all DRGs not listed in the previ-
ous groups. CV-related readmissions were classified
according to their associated DRG code. Revascularization
procedures were considered to be any hospitalization with
a DRG code for a PCI, stent, and/or CABG (DRGs 106,
518, 555–558).
Descriptive statistics were used to summarize the data.
The LOS for index hospitalizations was defined as the
maximum duration of days for all services that began on
the day of admission. In the follow-up period, the LOS
for services that overlapped in time was subsumed under
the service that had the maximum duration of days. In-
patient medical charges were calculated as the sum of
charges for all services that were associated with a
hospitalization. Patients without readmissions were
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or charges. Kaplan-Meier analyses were conducted to
look at time to rehospitalization for all-cause and for
CV-related events. Log-rank test was used to compare
the time to event for CV-related DRG rehospitalization
groups.Results
Patient characteristics are summarized in Table 1. Of the
6,687 ACS-PCI patients included, 5,174 (77.4%) were

















NSTEMI and UA 3411 (51.0)
Type of Stent at Index†
Drug-eluting stent 5534 (82.8)
Bare-metal stent 787 (11.8)
No stent 62 (0.9)
Unknown 304 (4.5)
Medical History in 12-month Baseline*†
Prior PCI 487 (7.3)
Prior CABG 51 (0.8)




Note: Percentages may not add to 100 due to rounding.
Abbreviations: ACS = acute coronary syndrome; CABG= coronary artery bypass
graft; NSTEMI = non-ST-segment elevation myocardial infarction;
PCI = percutaneous coronary intervention; SD = standard deviation; STEMI = ST-
segment elevation myocardial infarction; UA= unstable angina.
*ICD-9-CM Codes: Diabetes = 250.xx; Hyperlipidemia = 272.xx;
Hypertension= 401.xx-4-5.xx; STEMI = 410.xx; NSTEMI = 410.7; UA = 411.1.
†Type of Stent determined by Diagnosis Related Group code: Drug-eluting
stent = 557, 558; Bare-metal stent = 555,556; No stent = 518.56.5 years), 5,204 (77.9%) were located in the South and
Midwest, 4,821 (72.1%) had hypertension, 5,176 (77.4%)
had hyperlipidemia, and 1,777 (26.6%) had diabetes.
Drug-eluting stents were most frequently used, 5,534
(82.8%). Only 998 (14.9%) of patients were on clopido-
grel therapy prior to their index PCI event.
Of patients receiving DRG codes associated with PCI
at index, there were 3,245 DES patients with major car-
diovascular diagnosis (MCV dx, DRG 557) having a me-
dian charge of $47,510, median LOS of 3 days, and 9,313
total hospital days. In contrast, the 2,289 DES patients
without MCV dx (DRG 558) had a median charge of
$39,344, median LOS of 1 day, and 3,952 total hospital
days. At index hospitalization, 600 BMS patients with
MCV dx (DRG 555) had median charges of $40,370, me-
dian LOS of 3 days, and 1,715 total hospital days, while
BMS patients without MCV dx (DRG 556) had median
charges of $31,188, median LOS of 1 day, and 338 total
hospital days. The 62 patients receiving no stent (DRG
518) had a median charge of $28,435, median LOS of
1 day, and 105 total hospital days. Patients with DRGs
associated with PCI DES had higher total hospital days
than any other DRG at index hospitalization.
At 30 days post-index PCI hospitalization, 6,534
(97.7%) of patients were still enrolled; however, by
15 months continuous enrollment had dropped to 4,384
(65.6%). Of the initial cohort of 6,687 commercially
insured patients, 744 (11.1%) recorded an all-cause
rehospitalization within 30 days post-index PCI. Of the
4,384 patients that completed the 15-month follow-up
period, 2,126 (48%) patients recorded a rehospitalization
for any reason, many of which were for non-CV condi-
tions. However, 35.5% of the rehospitalizations were
associated with revascularization procedures (Figure 2).
Of the 744 patients who recorded an all-cause rehospita-
lization within 30 days post-index PCI, the majority of
the rehospitalizations were for revascularization proce-
dures 354 (47.6%), while 204 (27.4%) were for other non-
CV-related rehospitalizations. At 31 days to 15 months
post-index PCI, other non-CV-related rehospitalizations
accounted for 48.9% of rehospitalizations compared to
29.0% for revascularization procedures. Of the 1,367
patients recording a CV-related rehospitalization, 59.3%
were associated with revascularization procedures. CV-
related rehospitalization frequencies are summarized in
Table 2.
Table 3 displays median charge and total hospital days
for CV-related rehospitalization episodes. In general,
rehospitalizations associated with revascularization pro-
cedures costs more than those associated with chest
pain, heart failure/shock, stroke, or other CV-related
rehospitalizations. Among rehospitalizations, revascular-
ization episodes associated with PCI (DRG 518, 555–








Other CV: DRGs 
124, 125, 132, 144, 
515
6.1%







Figure 2 All-cause rehospitalizations by DRG code among ACS-PCI patients (n = 2,126)*. Note: Percentages may not add to 100 due to
rounding. Abbreviations: ACS = acute coronary syndrome; CV = Cardiovascular; DRG=Diagnosis Related Group codes, version 24;
PCI = percutaneous coronary intervention. *Rehospitalizations grouped by DRG codes.
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31-days to 15-months post-index.
Results for time to CV-related rehospitalization are
shown in Figure 3. Patients rehospitalized for revascular-
ization procedures had the shortest median time from
post-index PCI to rehospitalization when compared to
the other CV event groups. The median time to rehospi-
talization was 38.0 days (95% confidence interval [CI]:
33.0–45.0 days) for revascularization procedures;
59.5 days (CI: 31.0–106.0 days) for heart failure/shock,
58.5 days (CI: 24.0–144.0 days) for stroke, 72.0 days
(CI: 53.0–102.0 days) for chest pain, and 85.0 days
(CI: 72.0–102.0 days) for other CV-related events.
Discussion
This study adds to the current knowledge by reporting
and characterizing rehospitalizations following PCI in a








Note: Percentages may not add to 100 due to rounding.
Abbreviations: ACS = acute coronary syndrome; CV = cardiovascular; DRG =DiagnosiACS. Patients in this analysis were typically younger
than the populations reported by Curtis et al. and Jencks
et al., who analyzed Medicare claims data in which
patients were 65 years and older [10,11]. Our study
found that of our initial study cohort, 11.1% recorded an
all-cause rehospitalization within 30 days post-index
PCI. This is lower than results from Curtis et al. who
reported 14.6% [10]. However, an even more notable dif-
ference is that among all patients in our results from a
commercially insured cohort readmitted within 30 days
after the index PCI, 47.6% had a revascularization pro-
cedure compared to 27.5% in a Medicare population for
the comparable 30-day period [10]. Some of this differ-
ence may be explained by the fact that both Curtis et al.
and our study were unable to distinguish staged PCIs
and the associated planned rehospitalizations from those
that were unplanned [10]. Jencks et al. have suggested
that as many as 10% of the rehospitalizations aretions among ACS-PCI Patients
s post-index PCI 31 Days to 15 months post-index PCI






s Related Group codes version 24; PCI = percutaneous coronary intervention.
Table 3 Median Charges and Total Hospital Days for CV Rehospitalizations among ACS-PCI Patients
















106 Coronary Bypass with PTCA 9 $93266 8 70 4 $43843 6 22
518 PCI w/o stent 8 $24983 1 12 28 $28559 1 58
555 Bare metal stent with MCVdx 18 $28098 2 44 57 $45282 2 226
556 Bare metal stent w/o MCVdx 13 $23480 1 19 21 $28942 1 41
557 Drug eluting stent with MCVdx 64 $24753 2 138 95 $43879 2 205
558 Drug eluting stent w/o MCVdx 148 $34172 1 205 230 $37166 1 340
Chest Pain
143 Chest Pain 43 $7866 1 58 118 $9270 1 167
Heart Failure/Shock
127 Heart Failure & Shock 9 $10405 3 55 41 $13304 3 168
Stroke
014 Intracranial hemorr & stroke w infarct 3 $11100 3 13 7 $12026 4 45
Other CV
124 Circ disor except AMI, w cardiac cath &
complex dx
21 $14613 1 38 71 $17917 2 183
125 Circ disor except AMI, w cardiac cath
w/o complex dx
42 $16494 2 75 78 $17552 2 134
132 Atherosclerosis w CC 7 $10431 3 19 30 $7777 1 47
144 Oth circulatory system diagnoses w CC 11 $14584 3 44 12 $10805 3 43
515 Cardiac defibrillator impl w/o card cath 7 $120772 5 29 46 $97141 1 136
Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; CC = complications and comorbidities; CV = cardiovascular; cath = catheterization;
Circ = circulatory; DRG =Diagnosis Related Group codes version 24; dx = diagnosis; hemorr = hemmorage; impl = implant; infarct = infarction; disor = disorder;
LOS = length of stay; MCC =major complications and comorbidities; MCVdx =major cardiovascular diagnosis; oth = other; PCI = percutaneous coronary intervention;
PTCA= Percutaneous transluminal coronary angioplasty; w =with; w/o =without.
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staged PCI procedures rather than true unplanned revas-
cularizations [11]. Others have noted that PCI and other
interventional procedures are performed more often on
younger, less sick individuals than on older subjects, the
so called “treatment risk paradox” [15]. If so, the data we
report from a commercially insured population suggest
that the effect size of this paradox may be much larger
than expected considering randomized trials and guide-
lines report that the benefits of revascularization are
highest among moderate and high-risk patients [16-19].
Our population is very similar to the population
reported in Chastek et al., which looked at a commer-
cially insured population between the years 2000 and
2004 [20]. While they do not report on rehospitalizations
per se, in their study 24.5% of subjects experienced a sub-
sequent ischemic event within roughly a 3-year follow-up
period [20]. In our study, a total of 31.8% patients
recorded a rehospitalization for all-cause over a period of
up to 15 months. Chastek et al. report that the mean
LOS of the index hospitalization was approximately4.4 days, while we observed a mean LOS for index PCI of
2 to 3 days [20].
Results from this analysis are not applicable to indivi-
duals with Medicare, Medicaid, or dissimilar commercial
health plans since it was focused on commercially
insured patients who were primarily <65 years old. Al-
though we intentionally did not require continuous en-
rollment after the index PCI, one consequence of that
decision is that we do not have definitive outcomes data
on approximately 1 out of 3 patients, who could have ei-
ther transitioned to another health insurance plan, died,
or disenrolled for other reasons. Therefore, our study
was not suitable for determining overall mortality. The
economic results reflect charge data reported to a mana-
ged care organization (MCO) for billing purposes and
do not account for discounts or write-offs such that the
charges could be converted to actual costs. The data also
do not include detailed medical records and may be sub-
ject to coding and other errors in interpretation. For
example, details concerning the type of PCI (primary,
facilitated, or rescue) were unavailable.
Figure 3 Kaplan–Meier curves for time to CV-related rehospitalization by DRGs. Abbreviations: CV = cardiovascular; DRGs =Diagnosis
Related Groups; hosp= hospitalization; Revasc Proc = revascularization procedure.
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For ACS patients who underwent PCI, revascularization
procedures represented a large portion of rehospitaliza-
tions. Revascularization procedures appear to be the
most frequent, most costly, and earliest cause for rehos-
pitalization after ACS-PCI.
Additional file
Additional file 1: Diagnosis and procedure codes. *Diagnosis codes
are from ICD-9-CM. †Procedure codes are from ICD-9-CM Procedure Codes
for Hospital Inpatient Services: CPT-4W Procedure Codes/HCPCS Codes for
Hospital Outpatient Services and CPT-4W Codes for Physicians.
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